One-layer Versus Two-layer Duct-to-mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy

Sponsor
The Second Hospital of Anhui Medical University (Other)
Overall Status
Unknown status
CT.gov ID
NCT02511951
Collaborator
The First Affiliated Hospital of Anhui Medical University (Other)
114
1
2
40
2.8

Study Details

Study Description

Brief Summary

The aim of this study is to investigate a new pancreaticojejunal (PJ) anastomosis procedure named "One-layer duct-to-mucosa pancreaticojejunostomy" in pancreatoduodenectomy, which could provide a feasible option to pancreatic surgeons for patients with pancreaticoduodenectomy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: pancreaticojejunostomy
Phase 3

Detailed Description

Pancreaticoduodenectomy is a standard surgical approach for resectable pancreatic tumors and periampullary tumors. It is considered a safe procedure resulting from the continuous improvement in surgical techniques over the years. Although postoperative mortality has obviously decreased, pancreatic fistula is still a major challenge in pancreatic surgery and remains the major cause of postoperative morbidity and mortality after pancreaticoduodenectomy(PD), ranging from 3% to 30%.

Many risks factors have been shown to cause pancreatic fistula(PF) after the operation, including advanced age, prolonged operation time, intraoperative hemorrhage, BMI, soft pancreas, size of the main pancreatic duct and texture of the remnant pancreas. Among them, soft pancreatic texture without a dilated main pancreatic duct is regarded as the most important risk factor in predicting pancreatic fistula.

The serious consequences of pancreatic fistula result from the pancreatic juice becoming activated by the bile and intestinal fluid, which will eventually corrupt the PJ anastomosis and the surrounding normal tissues. The corrosion of the vasculature will lead to lethal hemorrhage, which is the main cause of mortality after pancreaticoduodenectomy. Furthermore, pancreatin, together with the bacteria in the alimentary tract, will lead to intra-abdominal infection and abscess. To reduce the pancreatic fistula rate, several techniques have been described as alternatives to the conventional PJ anastomosis. Duct-to-mucosa sutures, binding pancreaticojejunostomy and end-to-side invaginated fashion are widely used in the current clinical setting. Some non-randomized studies showed that the one-layer duct-to-mucosa method was a relatively safe approach. However, the prospective clinical study found that in comparison with the conventional two-layer duct-to-mucosa did obviously decrease the incidence of pancreatic fistula as well as other operative complications. The postoperative pancreatic fistula (POPF), which determines postoperative mortality, length of hospital stay, is dependent of its definition, and is reported in up to 16% of patients. The purpose of this study is to determine whether the new anastomosis called " one-layer duct-to-mucosa " pancreaticojejunostomy can reduce the POPF rate and downgrade compared with the common accepted duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy. This single-centre, open, randomized controlled trail is conducted following International Study Group on Pancreatic Fistula (ISGPF) criteria for pancreatic fistula (PF). The primary endpoint is the POPF rate, and others include overall postoperative complication rate and their severity reoperation rate and hospital stay.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
114 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: One-layer Versus Two-layer Duct-to-mucosa Pancreaticojejunostomy
Study Start Date :
Aug 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2018
Anticipated Study Completion Date :
Dec 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: one-layer duct-to-mucosa anastomosis

one-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.

Procedure: pancreaticojejunostomy
To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner. Two layer anatomosis with "Duct-to-Mucosa" pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.

Active Comparator: two-layer duct-to-mucosa anastomosis

two-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.

Procedure: pancreaticojejunostomy
To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner. Two layer anatomosis with "Duct-to-Mucosa" pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.

Outcome Measures

Primary Outcome Measures

  1. postoperative pancreatic fistula(POPF) rate [30 days]

    drainage of any measurable volume of fluid with an amylase content >3 times the upper normal serum value on or after postoperative day 3.

Secondary Outcome Measures

  1. Duration of postoperative hospital stay [30 days]

    Time from day of operation to day of discharge

  2. anastomosis time [1 hour]

    anastomosis time was calculated from begining to the end of pancreaticojejunostomy

  3. reoperation rate [30 days]

    The secondary endpoint will be the reoperation rate

  4. Morbidity [30 days]

    the severity of complications was graded according to the Clavien-Dindo classification

  5. Mortality [30 days]

    operative mortality was defined as any death resulting from a complication during surgery

  6. Biliary leakage [30]

    biliary leakage was documented in line with the International Study Group of Liver Surgery(ISGLS) definitions and grading systems

  7. Blood transfusion [2 days]

    Administration of blood transfusions is documented for the intraoperative and postoperative period until 48 hours postoperatively

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Both male and female, aged 18 to 80;

  • Patients scheduled to undergo pancreaticoduodenectomy;

  • Provided written informed consent;

Exclusion criteria:
  • Patients with severe cardiopulmonary disorder that might prolong the postoperative hospital stay;

  • Patients who had a previous pancreatic operation;

  • Patients with an immunodeficiency;

  • Patients who underwent an emergency operation;

  • Pregnant patients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 the Second Affiliated Hospital of Anhui Medical University Hefei Anhui China 230022

Sponsors and Collaborators

  • The Second Hospital of Anhui Medical University
  • The First Affiliated Hospital of Anhui Medical University

Investigators

  • Principal Investigator: xiaoping geng, professor, the vice President of the second affiliated hospitalof Anhui medical university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
xpgeng, vice-president, The Second Hospital of Anhui Medical University
ClinicalTrials.gov Identifier:
NCT02511951
Other Study ID Numbers:
  • ahykdxdefsyy11
First Posted:
Jul 30, 2015
Last Update Posted:
Aug 18, 2015
Last Verified:
Aug 1, 2015
Keywords provided by xpgeng, vice-president, The Second Hospital of Anhui Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2015